• Bay 11-7821 (BAY 11-7082): Powering Inflammatory Signaling R

  2026-07-03

  Bay 11-7821 (BAY 11-7082) delivers robust, selective NF-κB pathway inhibition for dissecting inflammation and apoptosis in translational research. Its versatility in cell-based and in vivo workflows—backed by APExBIO’s reliability—empowers reproducible, high-impact results across cancer, immunology, and sepsis models.

• Verteporfin (SKU A8327): Reliable Photodynamic and Autophagy

  2026-07-03

  This article bridges real-world laboratory challenges in cell viability, apoptosis, and autophagy assays with evidence-based solutions using Verteporfin (SKU A8327). By guiding researchers through scenario-driven Q&A, it highlights the reproducibility, mechanistic depth, and workflow flexibility of Verteporfin from APExBIO.

• Canagliflozin in Renal Bioenergetics: Mitochondrial Dynamics

  2026-07-02

  Explore how Canagliflozin, a potent SGLT2 inhibitor, modulates mitochondrial bioenergetics and structure in diabetic kidney research. This article uniquely dissects ultrastructural and metabolic impacts, guiding advanced assay design for renal and metabolic studies.

• iRhom2 Regulates Olfactory Receptor Adaptation in Mice

  2026-07-02

  Azzopardi et al. (2024) reveal that iRhom2, previously known for its role with ADAM17 in immune signaling, is selectively expressed in mouse olfactory sensory neurons. Their study demonstrates that iRhom2 mediates odor-induced transcriptional adaptation, uncovering a molecular feedback loop with broad implications for understanding sensory regulation.

• Leptin (116-130), amide, mouse: Applied Workflows for Metabo

  2026-07-01

  Leptin (116-130), amide, mouse empowers researchers to dissect energy homeostasis and immune-metabolic signaling with unmatched precision. This guide delivers actionable workflows, troubleshooting insights, and advanced applications that leverage this potent adipocyte-derived hormone fragment.

• Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one): P

  2026-07-01

  Apigenin stands out as a dual-action research tool for cancer and neurodegeneration, with robust support for HDAC inhibition and neuroprotective mechanisms. This article unpacks experimental workflows, troubleshooting insights, and the translational edge that APExBIO’s Apigenin brings to advanced bench studies.

• SB 431542: ALK5 Inhibitor Workflows for TGF-β Pathway Dissec

  2026-06-30

  SB 431542 enables researchers to selectively block ALK5 and dissect TGF-β-driven mechanisms in both in vitro and in vivo models, offering precise control over Smad2 phosphorylation and cellular differentiation. APExBIO’s reliable formulation supports high reproducibility for cancer, stem cell, and immunology research, with troubleshooting strategies to optimize experimental outcomes.

• Verteporfin (CL 318952): Redefining Cancer Cell Stiffness As

  2026-06-30

  Explore how Verteporfin enables high-precision modulation of cancer cell stiffness and apoptosis, bridging photodynamic therapy with advanced mechanobiological research. This article reveals data-driven insights and unique assay strategies for Verteporfin in oncology.

• Bradykinin B2 Receptors Modulate Peristalsis in Guinea Pig I

  2026-06-29

  This study delivers the first direct evidence that bradykinin B2 receptors inhibit the peristaltic reflex in the guinea pig ileum by increasing the pressure threshold required for contraction. These findings provide a mechanistic basis for targeting bradykinin signaling in gastrointestinal and potentially cardiovascular research.

• Etomoxir in Immunometabolic Assays: Protocols and Pitfalls

  2026-06-29

  Etomoxir, a potent CPT-1 inhibitor from APExBIO, is powering breakthroughs in fatty acid oxidation pathway research and immunometabolic profiling. This article demystifies protocol enhancements, troubleshooting, and comparative advantages for translational studies involving immune modulation and metabolic disorder models.

• Etomoxir in Fatty Acid Oxidation Pathway Research: Protocols

  2026-06-28

  Etomoxir (R-(+)-Etomoxir) is a gold-standard CPT-1 inhibitor for dissecting fatty acid oxidation and immunometabolic crosstalk. This guide details actionable workflows, troubleshooting tips, and protocol parameters rooted in the latest evidence, enabling reproducible and insightful metabolic disorder research.

• Estrogen Drives PTC Progression via ERα/KRT19: Mechanistic I

  2026-06-27

  This study uncovers the mechanistic role of estrogen in enhancing papillary thyroid carcinoma (PTC) progression through the ERα/KRT19 signaling axis. By integrating transcriptomic, bioinformatic, and functional assays, the authors provide compelling evidence for ERα and KRT19 as key mediators of estrogen-driven proliferation, migration, and invasion in PTC, offering new avenues for biomarker and therapeutic development.

• Alfuzosin HCl: Applied Protocols and Innovations in BPH Rese

  2026-06-26

  Alfuzosin HCl is redefining benign prostatic hyperplasia research with its selective α1 adrenoceptor antagonism and robust solubility profile. This article unpacks data-driven workflows, advanced gastroretentive delivery applications, and practical troubleshooting, leveraging APExBIO's trusted quality to optimize experimental outcomes.

• Doxycycline Hyclate: Advancing BBB Protection in Translation

  2026-06-26

  Doxycycline hyclate, a semisynthetic tetracycline, is redefining the translational research landscape for neurovascular disorders through its robust and selective inhibition of matrix metalloproteinases (MMPs). Recent studies demonstrate its capacity to preserve blood-brain barrier (BBB) integrity and mitigate neuronal apoptosis in arsenic-induced cognitive impairment models. This thought-leadership article bridges mechanistic insight with practical guidance, positioning Doxycycline hyclate as a strategic asset for researchers exploring blood-brain barrier disruption, neuroinflammation, and cross-domain applications.

• Auranofin: Applied Protocols for Cancer and Redox Research

  2026-06-25

  Auranofin, a gold-standard thioredoxin reductase inhibitor, empowers researchers to dissect redox regulation, apoptosis, and radiosensitization in cancer and infection models. This article details actionable workflows, troubleshooting insights, and practical innovations inspired by cytoskeleton-dependent autophagy, setting Auranofin apart for advanced mechanistic and translational applications.

15228 records 1/1016 page Next 12345 下5页 Last page